Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bioventus Gains Access to Knee Osteoarthritis Pain Relief Treatments - Orthopedic Design & Technology
OEM News

Bioventus Gains Access to Knee Osteoarthritis Pain Relief Treatments

Company is leveraging the treatment options through the CVS Caremark Formulary.

Beginning Jan. 1, Bioventus, a global leader in Innovations For Active Healing, will gain preferred access through the CVS Caremark Formulary, to DUROLANE, GELSYN-3, and SUPARTZ FX, for the treatment of knee osteoarthritis (OA) pain. CVS Caremark manages the drug benefits for more than 40 million lives, which includes the prescription drug benefits of 6 million Aetna members.
 
DUROLANE, is a single-injection, GELSYN-3, a three-injection, and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.

“CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the US,” said John Nosenzo, chief commercial officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters